Trial Results

Protocol and Statistical Analysis Plan
Available Languages: English
View PDF

Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment

Study Identifier:
ECU-aHUS-403
ClinicalTrials.gov Identifier:
NCT02614898
EudraCT Identifier:
2015-003135-35
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other

Study Details

Medical Condition
  • Unmapped
Study Drug
    Date
    Nov 2015 - Oct 2017
    Phase 1
    Phase 2
    Phase 3
    Phase 4
    N/A
    Patient Requirements
    Sex: Female & Male
    Age: N/A - N/A
    Requirements Information
    Sex
    Female & Male
    Age
    N/A - N/A

    Study Details

    Medical Condition
    • Unmapped
    Study Drug
      Date
      Nov 2015 - Oct 2017
      Phase 1
      Phase 2
      Phase 3
      Phase 4
      N/A
      Patient Requirements
      Sex: Female & Male
      Age: N/A - N/A years
      Requirements Information

      Protocol Summary

      This was a prospective, open-label study with no participant randomization. Treatment for aHUS was observational and at the discretion of the treating physician. The purpose of this study was to assess disease manifestations of complement-mediated thrombotic microangiopathy (TMA) and evaluate potential clinical predictors of disease manifestations and progression in participants with aHUS with or without eculizumab treatment in the clinical setting.

      Trial Locations

      Location
      Status
      Location
      Clinical Trial Site
      Washington, District of Columbia, United States, 20007
      Status
      N/A
      Location
      Clinical Trial Site
      Atlanta, Georgia, United States, 30322
      Status
      N/A
      Location
      Clinical Trial Site
      Chicago, Illinois, United States, 60611
      Status
      N/A
      Location
      Clinical Trial Site
      Boston, Massachusetts, United States, 02115
      Status
      N/A
      Location
      Clinical Trial Site
      Hackensack, New Jersey, United States, 07601
      Status
      N/A
      Location
      Clinical Trial Site
      Charlotte, North Carolina, United States, 28203
      Status
      N/A